CS Diagnostics Corp.

CSDX: 8-K · restatement

CS Diagnostics Corp announced that its Board has determined previously issued financial statements for fiscal years 2022 through 2025 should no longer be relied upon. This decision follows a review initiated by communications with SEC staff regarding the company's historical accounting and audit history. Management identified that an approximately $499.4 million intangible asset recorded in connection with a September 2023 transaction was improperly recognized. The asset is expected to be removed from the balance sheet, requiring a restatement that will materially reduce total assets and stockholders' equity. Additionally, the company cannot rely on audit reports issued by its former auditor, Olayinka Oyebola & Co., due to SEC regulatory restrictions. The company has engaged Shah Teelani & Associates as its new independent auditor to re-audit the affected periods and assist with the restatement.

SEC 8-K•4mo ago

CSDX: NT 10-Q · late filing

CS Diagnostics Corp. filed a Form 12b-25 notification on May 15, 2026, stating it is unable to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, within the prescribed time period. The company cited the need for additional time to complete the preparation and review of its financial statements and related disclosures, as well as for its independent registered public accounting firm to complete its review procedures. The registrant anticipates significant changes in results of operations compared to the prior fiscal year but cannot provide a reasonable estimate until the financial closing procedures are completed.

SEC NT 10-Q•5mo ago